TC BioPharm (TCBP) declared a special dividend of 0.25 ADS per ADS held, pending shareholder approval on December 30, 2024. The company, focused on gamma-delta T-cell cancer therapies, is conducting pivotal clinical trials for acute myeloid leukemia (AML) using its CryoTC technology. Despite the dividend announcement, TCBP stock fell 1.94% pre-market.
Dragonfly Therapeutics, a clinical-stage biotech company, showcased preclinical data for its novel immunotherapies, DF6215 and DF9001, at the Society for Immunotherapy of Cancer (SITC) Annual Conference. DF6215, an engineered IL-2 cytokine, demonstrated superior therapeutic benefits compared to traditional IL-2 therapies, while DF9001, an EGFR-targeting TriNKET, exhibited potent anti-tumor activity through both EGFR-signal inhibition and immune-mediated mechanisms. Both candidates showed promising safety profiles, highlighting their potential for treating advanced solid tumors.
Breast cancer is a global health concern, but early detection and advancements in treatment are improving survival rates. This article delves into the importance of mammography, explores the latest research on hormone replacement therapy and its link to breast cancer risk, and discusses the impact of AI and 3D mammography on detection. Additionally, it provides insights into the most common risk factors, preventative measures, and cutting-edge treatment options, including immunotherapy and targeted therapies for triple-negative breast cancer. Experts weigh in on the crucial role of genetic screening and risk-reducing strategies for women with high genetic risk.
Aura Biosciences, Inc. (AURA) has released encouraging early data from its ongoing Phase 1 trial of bel-sar (AU-011) for non-muscle-invasive bladder cancer (NMIBC). The data suggests bel-sar with light activation could be a promising new treatment option with rapid tumor response and potential for durable effects.
Gritstone Bio’s GRANITE, an individualized neoantigen-targeting immunotherapy, demonstrated potential in treating microsatellite-stable colorectal cancer (MSS-CRC). While the interim Phase 2 data showed positive results, particularly in patients with lower disease burden, the stock price declined due to concerns about the overall impact and future development plans. The company will discuss the progression-free survival data with the FDA and explore potential Phase 2 or 3 trials using ctDNA levels as eligibility criteria.
The FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy for adult patients with resectable early-stage non-small cell lung cancer (NSCLC) who do not have certain genetic mutations. This approval is based on positive results from the AEGEAN trial, demonstrating a significant reduction in the risk of recurrence and improved pathological complete response rates. Imfinzi is also being evaluated for use in limited-stage small cell lung cancer.
The global mantle cell lymphoma treatment market is experiencing a surge, driven by advancements in targeted therapies and immunotherapy. The market is anticipated to reach US$ 2.53 billion in 2024 and expand at a CAGR of 8.6% to reach US$ 5.77 billion by 2034. Key drivers include the increasing incidence of mantle cell lymphoma, personalized medicine approaches, and emerging research in the field.
A new case report suggests that CAR T-cell therapy, typically used for cancer treatment, may be effective in treating Stiff Person Syndrome (SPS), a rare neurological disorder characterized by painful muscle spasms. The therapy successfully reduced symptoms and improved mobility in a patient with SPS, offering hope for a new treatment option.
For the first time, scientists have tested an mRNA vaccine in a patient with glioblastoma, an aggressive type of brain cancer. The vaccine triggered a strong immune response, offering hope for a new treatment approach. The vaccine was created by extracting genetic material from the patient’s tumor and replicating it to make mRNA, which then instructed the body to attack the cancer cells.
Springtime can spell misery for allergy sufferers, but there are steps you can take to minimize your symptoms. Avoid exposure to pollens, monitor pollen counts, and consider over-the-counter nasal sprays or antihistamines. For severe allergies, immunotherapy can provide long-term relief. Remember, climate change is contributing to longer and more intense allergy seasons, so be prepared.
